Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12525MR)

This product GTTS-WQ12525MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ12525MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ16008MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ZW-25
GTTS-WQ12454MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NKTR-214
GTTS-WQ7661MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GEN-1029
GTTS-WQ335MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 1F5
GTTS-WQ13201MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-04950615
GTTS-WQ2303MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ALXN-1210
GTTS-WQ507MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 47H4
GTTS-WQ11828MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MK-4280
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW